Compare Incyte Corporation (INCY) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Rivian Automotive, Inc. — how do they compare? Incyte Corporation trades at $117.94 (market cap $23.11B), while Rivian Automotive, Inc. trades at $17.64 (market cap $24.95B). The key difference: Incyte Corporation and Rivian Automotive, Inc. are close in size by market cap, and Incyte Corporation is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals.
| INCY | RIVN | |
|---|---|---|
Market Cap | $23.11B | $24.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $22.45 |
52-Week Low | $67.38 | $11.64 |
Enterprise Value | $19.13B | $26.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Rivian Automotive (RIVN) trades at $17.19, down 1.52% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company continues to post significant losses, with a net income margin of -63.62% for 2025, though revenue growth has been steady and recent quarterly EPS have beaten expectations. Cash flow remains negative, but the trend shows improvement from prior years. Analyst sentiment is mixed with a consensus price target of $19.22.
The outlook hinges on successful execution of the R2 vehicle launch and path to profitability. Investment opportunity lies in the potential for market share gains in the EV sector, but risks include high cash burn, competitive pressures, and reliance on capital markets for funding. The stock's performance will be closely tied to quarterly earnings and production updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
